Could the largest market for the new schizophrenia drug xanomeline and trospium chloride (Cobenfy) be in Alzheimer's disease ...

Research analysts at William Blair upped their Q4 2024 earnings estimates for Bristol-Myers Squibb in a report released on Tuesday, January 21st. William Blair analyst M. Phipps now forecasts that the ...

Stifel initiated coverage on Cytokinetics Incorporated (NASDAQ:CYTK), noting the company’s catalyst rich one to two years.

From Novo Holding's purchase of Catalent to BMS's Karuna acquisition, here are 10 of the most significant M&A moments of 2024.

Louisiana has six seats in the House of Representatives, four Republican and two Democrat. There are three ways for a sitting ...

Neomorph is building out its supply of Big Pharma partnerships, this time stamping down an option-to-license pact with AbbVie that centers around the biotech’s molecular glue platform. | Neomorph is ...

CARE Pharmacies appointed Ryan Hollingsworth, Natalie Ryan and Steven Pieri to its 2025 board of directors, and Lionel Phillips will serve as vice chairman on its executive committee.

Bristol Myers Squibb exercises an exclusive license option for ArsenalBio’s AB-4000 series programs -- -- ArsenalBio is eligible for additional milestone payments and royalties as the programs ...

The American College of Cardiology announced the late-breaking science lineup for its Scientific Session to be held March ...

In a report released on January 21, Akash Tewari from Jefferies reiterated a Buy rating on Pfizer (PFE – Research Report). The company’s shares ...

In a report released on January 21, Akash Tewari from Jefferies reiterated a Buy rating on Merck & Company (MRK – Research Report). The ...

2025 is set to be a game-changing year for cancer research, with cutting-edge therapies and technologies driving unprecedented progress in oncology.